- Policy
- Special authorization requested for COVAX-Pfizer vaccine
- by Kim, Jung-Ju Feb 5, 2021 05:50am
- The South Korean disease control authority is requesting the health authority to grant a special approval on 117,000 doses of Pfizer vaccines to be supplied to the country by COVAX Facility. Under the supply agreement with COVAX Facility, the vaccines would be promptly introduced to South Korea for inoculation starting from this month.
- Company
- Viatris’ Korean subsidiary has changed the name to Viatris
- by Feb 4, 2021 10:22am
- The Korean corporate name of the global healthcare company Viatris group will be officially changed to Viatris Korea from the 1st. Viatris’ Korean subsidiary (CEO: He-young Lee) was launched in November 2020 by combining Upjohn, a business division of global Pfizer, and Mylan, a global healthcare company. As the procedure for changing th
- Policy
- The approval of Atozet’s generics was also difficult
- by Lee, Tak-Sun Feb 4, 2021 06:09am
- It has become difficult for generic companies of MSD's hyperlipidemia complex Atozet to approve items in January. If the approval was obtained in January, the drug for data-based re-evaluation commissioned by Chong Kun Dang and the timing of the registration were the same, so that within 20 drugs could be applied. However, it is known that th
- “Developing lazertinib as dramatic as movie production”
- by Moon, sung-ho Feb 4, 2021 06:09am
- The developer of South Korean-made lung cancer new drug Leclaza (lazertinib), Professor Cho Byoungchul at Yonsei Cancer Center compared his dramatic five-year journey of seeking South Korea’s Ministry of Food and Drug Safety (MFDS) approval on the drug as a movie production; discovering the candidate substance was a casting call, clinical findi
- Company
- Eisai Parkinson’s disease drug Equifina listed and launched
- by Eo, Yun-Ho Feb 4, 2021 06:08am
- Eisai’s Parkinson’s disease treatment Equifina has been released to the South Korean market on Feb. 2 with the National Health Insurance (NHI) reimbursement. The Ministry of Health and Welfare (MOHW) notice issued on Jan. 29 granted the NHI benefit on Equfina (safinamide) as an adjuvant treatment to levodopa for idiopathic Parkinson’s
- Company
- Stomach ulcer drug rebamipide market makes over KRW 100 bln
- by An, Kyung-Jin Feb 3, 2021 06:10am
- The impurity contamination in ranitidine was discovered in 2019 has in turn expanded a gastritis treatment rebamipide market. Although the market was sluggish for a long time, rebamipide prescription surged and broke through the 100 billion won point last year. The impurity contamination incident impacted the entire stomach disorder drug market
- Company
- Pfizer's Vizimpro can be prescribed at general hospitals
- by Eo, Yun-Ho Feb 3, 2021 06:09am
- Pfizer's EGFR TKI and Vizimpro are now available in general hospitals with insurance benefits. According to related industries, Vizimpro (Dacomitinib monohydrate), a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), listed in December. It passed the drug committee (DC) of general hospitals such as I
- Policy
- Re-evaluation of benefits, scheduled to be conducted annuall
- by Kim, Jung-Ju Feb 3, 2021 06:09am
- At the end of last year, the government is about to begin the main evaluation of the five active ingredients following the pilot project of reevaluation of the adequacy of registered drugs for Choline alfoscerate (reevaluation of the benefits of registered drugs). It seems to have taken into account the time taken for the procedure, such as revi
- Company
- Menarini Korea presents Fulcare's digital campaign video
- by Feb 3, 2021 06:09am
- Menarini Korea (CEO Hyeyoung Park) announced on the 2nd that it is releasing a new digital campaign video 'Re, Start Again' of Fulcare, a treatment for nail athlete's foot. The new campaign was planned as part of Fulcare's brand campaign 'Clear Again' from 2020. By emphasizing the keyword 'again' by focusing on 're' at the back of Fulcare
- Product
- Frequently consumed OTC drug prices differ in pharmacies
- by Kang, Shin-Kook Feb 3, 2021 06:09am
- The price gap of Tyrenol ER, Gelfos and Tak-Sen widened up to 150 percent among different pharmacies selling the drugs, which contrasted against high-priced bundle-packaged drugs showing barely any gap. Daily Pharm surveyed 22 pharmacies in Incheon for their frequently sold over-the-counter (OTC) drug retail prices as of February, and it fou
